Compliance with the guidelines for laboratory monitoring of patients treated with lithium: A retrospective follow-up study among ambulatory patients in the Netherlands.

Autor: Nederlof M; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.; Brocacef Ziekenhuisfarmacie, Maarssen, The Netherlands., Egberts TC; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.; Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands., van Londen L; Transparant, Centre for Psychiatry, Leiden, The Netherlands.; Department of Psychiatry, Leiden University Medical Center, Leiden, The Netherlands., de Rotte MC; SCAL Medical Diagnostics, Leiden, The Netherlands., Souverein PC; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands., Herings RM; PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands.; Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, Netherlands., Heerdink ER; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.; Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands.; Research Group Innovation of Pharmaceutical Care, University of Applied Sciences Utrecht, Utrecht, The Netherlands.

Publikováno v: Bipolar disorders [Bipolar Disord] 2019 Aug; Vol. 21 (5), pp. 419-427. Date of Electronic Publication: 2019 Jan 02.

Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis.

Autor: de Rotte MC; Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, Netherlands., den Boer E; Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, Netherlands., de Jong PH; Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands., Pluijm SM; Department of Pediatric Hemato-Oncology, Erasmus University Medical Center, Rotterdam, Netherlands., Ćalasan MB; Department of Pediatric Immunology, University Medical Center Utrecht, Wilhelmina Children's hospital, Utrecht, Netherlands., Weel AE; Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands., Huisman AM; Interne Specialismen Rijnmond Noord, Sint Franciscus Hospital, Rotterdam and IJsselland Hospital, Capelle aan de IJssel, Netherlands., Gerards AH; Department of Rheumatology, Vlietland Hospital, Schiedam, Netherlands., van Schaeybroeck B; Department of Rheumatology, Albert Schweitzer Hospital, Dordrecht, Netherlands., Wulffraat NM; Department of Pediatric Immunology, University Medical Center Utrecht, Wilhelmina Children's hospital, Utrecht, Netherlands., Lindemans J; Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, Netherlands., Hazes JM; Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands., de Jonge R; Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, Netherlands.

Publikováno v: Annals of the rheumatic diseases [Ann Rheum Dis] 2015 Feb; Vol. 74 (2), pp. 408-14. Date of Electronic Publication: 2013 Dec 02.

Determinants of erythrocyte methotrexate polyglutamate levels in rheumatoid arthritis.

Autor: den Boer E; From the Department of Clinical Chemistry; Department of Rheumatology; Department of Pediatric Hemato-Oncology; Erasmus University Medical Center, Rotterdam, the Netherlands.E. den Boer, MSc; M.C.J.F. de Rotte, PharmD; S.G. Heil, PhD; R. de Jonge, PhD, Department of Clinical Chemistry; J.M. Hazes, MD, PhD, Department of Rheumatology; S.M.F. Pluijm, PhD, Department of Pediatric Hemato-Oncology, Erasmus University Medical Center., de Rotte MC; From the Department of Clinical Chemistry; Department of Rheumatology; Department of Pediatric Hemato-Oncology; Erasmus University Medical Center, Rotterdam, the Netherlands.E. den Boer, MSc; M.C.J.F. de Rotte, PharmD; S.G. Heil, PhD; R. de Jonge, PhD, Department of Clinical Chemistry; J.M. Hazes, MD, PhD, Department of Rheumatology; S.M.F. Pluijm, PhD, Department of Pediatric Hemato-Oncology, Erasmus University Medical Center., Pluijm SM; From the Department of Clinical Chemistry; Department of Rheumatology; Department of Pediatric Hemato-Oncology; Erasmus University Medical Center, Rotterdam, the Netherlands.E. den Boer, MSc; M.C.J.F. de Rotte, PharmD; S.G. Heil, PhD; R. de Jonge, PhD, Department of Clinical Chemistry; J.M. Hazes, MD, PhD, Department of Rheumatology; S.M.F. Pluijm, PhD, Department of Pediatric Hemato-Oncology, Erasmus University Medical Center., Heil SG; From the Department of Clinical Chemistry; Department of Rheumatology; Department of Pediatric Hemato-Oncology; Erasmus University Medical Center, Rotterdam, the Netherlands.E. den Boer, MSc; M.C.J.F. de Rotte, PharmD; S.G. Heil, PhD; R. de Jonge, PhD, Department of Clinical Chemistry; J.M. Hazes, MD, PhD, Department of Rheumatology; S.M.F. Pluijm, PhD, Department of Pediatric Hemato-Oncology, Erasmus University Medical Center., Hazes JM; From the Department of Clinical Chemistry; Department of Rheumatology; Department of Pediatric Hemato-Oncology; Erasmus University Medical Center, Rotterdam, the Netherlands.E. den Boer, MSc; M.C.J.F. de Rotte, PharmD; S.G. Heil, PhD; R. de Jonge, PhD, Department of Clinical Chemistry; J.M. Hazes, MD, PhD, Department of Rheumatology; S.M.F. Pluijm, PhD, Department of Pediatric Hemato-Oncology, Erasmus University Medical Center., de Jonge R; From the Department of Clinical Chemistry; Department of Rheumatology; Department of Pediatric Hemato-Oncology; Erasmus University Medical Center, Rotterdam, the Netherlands.E. den Boer, MSc; M.C.J.F. de Rotte, PharmD; S.G. Heil, PhD; R. de Jonge, PhD, Department of Clinical Chemistry; J.M. Hazes, MD, PhD, Department of Rheumatology; S.M.F. Pluijm, PhD, Department of Pediatric Hemato-Oncology, Erasmus University Medical Center. r.dejonge@erasmusmc.nl.

Publikováno v: The Journal of rheumatology [J Rheumatol] 2014 Nov; Vol. 41 (11), pp. 2167-78. Date of Electronic Publication: 2014 Sep 15.

Association of low baseline levels of erythrocyte folate with treatment nonresponse at three months in rheumatoid arthritis patients receiving methotrexate.

Autor: de Rotte MC; Erasmus University Medical Center, Rotterdam, The Netherlands., de Jong PH, Pluijm SM, Calasan MB, Barendregt PJ, van Zeben D, van der Lubbe PA, de Sonnaville PB, Lindemans J, Hazes JM, de Jonge R

Publikováno v: Arthritis and rheumatism [Arthritis Rheum] 2013 Nov; Vol. 65 (11), pp. 2803-13.

ABCB1 and ABCC3 gene polymorphisms are associated with first-year response to methotrexate in juvenile idiopathic arthritis.

Autor: de Rotte MC; Department of Clinical Chemistry, Erasmus MC, University Medical Center, Rotterdam, The Netherlands., Bulatovic M, Heijstek MW, Jansen G, Heil SG, van Schaik RH, Wulffraat NM, de Jonge R

Publikováno v: The Journal of rheumatology [J Rheumatol] 2012 Oct; Vol. 39 (10), pp. 2032-40. Date of Electronic Publication: 2012 Aug 01.